European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading

MT Newswires Live
29 Jan

European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.81% to 1,363.17 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by accommodations booking company trivago (TRVG) and biopharmaceutical company argenx (ARGX), which rose 2.6% and 1.5% respectively. They were followed by software firm SAP (SAP) and energy company Equinor (EQNR), which were up 1.4% and 1.3% respectively.

The decliners from continental Europe were led by biopharmaceutical companies DBV Technologies (DBVT) and Genfit (GNFT), which fell 5.2% and 2.8% respectively. They were followed by biopharmaceutical company Grifol (GRFS) and furniture maker Natuzzi (NTZ), which dropped 2.2% and 0.8% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which increased 4.3% and 3% respectively. They were followed by biopharmaceutical companies TC Biopharm (TCBP) and Akari Therapeutics (AKTX), which rose 2.4% and 2.3% respectively.

The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and biopharmaceutical company Amarin (AMRN), which lost 6.4% and 3.9% respectively. They were followed by alcoholic beverage company Diageo (DEO) and pharmaceutical company Silence Therapeutics (SLN), which were down 1.8% and 1.5% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10